Trial Updates

Simultaneous comparison of 25 acute migraine medications: a big data analysis 4:07
Simultaneous comparison of 25 acute migraine medications: a big data analysis
Chia-Chun Chiang • 26 Apr 2023
Advancing myasthenia gravis treatment: RAISE trial of zilucoplan 2:27
Advancing myasthenia gravis treatment: RAISE trial of zilucoplan
James F. Howard Jr. • 26 Apr 2023
Analysis of acute migraine medications: bridging the gap between research & real-world experiences 1:26
Analysis of acute migraine medications: bridging the gap between research & real-world experiences
Chia-Chun Chiang • 26 Apr 2023
Tenecteplase increasingly implemented as standard of care in acute ischemic stroke 1:53
Tenecteplase increasingly implemented as standard of care in acute ischemic stroke
Johanna Ospel • 13 Apr 2023
Association of B-cell subsets and AQP4 antibody titers with disease activity in NMOSD 2:51
Association of B-cell subsets and AQP4 antibody titers with disease activity in NMOSD
Friedemann Paul • 27 Apr 2023
Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study 1:56
Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study
Friedemann Paul • 27 Apr 2023
Study design for the PREVAIL trial: Phase III study of ALXN1720 in adults with myasthenia gravis 1:52
Study design for the PREVAIL trial: Phase III study of ALXN1720 in adults with myasthenia gravis
James F. Howard Jr. • 26 Apr 2023
ND0612 vs oral immediate-release levodopa/carbidopa in patients with PD and motor fluctuations 3:31
ND0612 vs oral immediate-release levodopa/carbidopa in patients with PD and motor fluctuations
Alberto Espay • 27 Apr 2023
Zavegepant nasal spray for the acute treatment of migraine with and without aura 3:07
Zavegepant nasal spray for the acute treatment of migraine with and without aura
Timothy Smith • 26 Apr 2023
MND-SMART: the adaptive platform trial investigating potential treatments for MND 3:22
MND-SMART: the adaptive platform trial investigating potential treatments for MND
Jane Haley • 24 Apr 2023
Key findings from Phase IIa study of PrimeC in ALS patients 3:07
Key findings from Phase IIa study of PrimeC in ALS patients
Shiran Salomon-Zimri • 27 Mar 2023
Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease 2:02
Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease
Gennaro Pagano • 5 Apr 2023
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial 10:55
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial
Shiran Salomon-Zimri • 27 Mar 2023
Open label extension of prasinezumab in Parkinson’s disease: 1 year updates 0:55
Open label extension of prasinezumab in Parkinson’s disease: 1 year updates
Gennaro Pagano • 5 Apr 2023
Phase III trial on mindfulness added to treatment as usual for chronic migraine & MOH 2:54
Phase III trial on mindfulness added to treatment as usual for chronic migraine & MOH
Licia Grazzi • 16 Mar 2023
Self-reported adherence and safety from the MASTER-2 & CLICK-MS studies of cladribine in MS patients 3:21
Self-reported adherence and safety from the MASTER-2 & CLICK-MS studies of cladribine in MS patients
Emily Evans • 21 Feb 2023
The content of VJNeurology is intended for healthcare professionals